Quote:Do we think that Leronlimab is a time saving immunotherapy drug that allows time by stopping metastasizing so our immune system can kill the tumors?
After chemotherapy or radiation you'll often see reoccurrence of cancer. That can be caused by damage to DNA of tumor cells but with subsequent repair. Chemo or radiation can also cause the tumor to fragment and those surviving cells from fragmentation that undergo DNA repair can effectively become circulating tumor cells. Leronlimab will downregulate circulating tumor cells via CCR5/CCL5 non-binding and knocking down metastasization. Leronlimab also blocks tumor DNA repair.
Chemotherapy and radiation can cause immune suppression lowering the amount of tumor killing T-cells. Leronlimab boosts killer T-cells. It downregulates Tregs, PD-1/PD-L1 and other tumor protectant factors (the drug used in the linked article lowers PD-1) and reduces the growth of blood vessels which are necessary to tumor growth.
https://www.nbcnews.com/news/amp/rcna203038
Quote:Our method of action appears to be stopping the CCR5 receptors on some cancer cells but not all cells because the CCR5 receptors are not on all cancers? Is this true?
You're going to see CCR5 expression on tumors and in the tumor microenvironment. What is important is the level of increase in CCR5. The greater the increase in CCR5 the better leronlimab will work because increases in CCR5 equate to a rise in factors that promote cancer. As an example breast tissue under normal conditions has a fairly low level of CCR5 expression but with breast cancer you can see a dramatic rise. What can hamper the increase in CCR5 is genetic variations unrelated to CCR5 delta 32 deletion. From everything I've seen leronlimab should be of some use in a minimum of 80% of cancer types.
Quote:Ohm speaks of using Leronlimab with other drugs. Is this to enhance the immune response? Or to attack the cancer cells?
Both
Quote:Would Leronlimab work better if it was a first choice drug and not used after immune system hammering chemo?
Chemotherapy, especially targeted agents like Trodelvy have their own mode of killing that should enhance leronlimab's ability to kill tumors. Although I would like to see a head to head animal study with Trodelvy and leronlimab vs. leronlimab to see how much Trodelvy adds to leronlimab's abilities. Leronlimab should definitely be used as a first line treatment because the earlier you can treat the cancer the better the chance is of eradicating it.
38
